The Scientific Advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was held to discuss Nevrargenics’ Motor Neurone Disease drug candidate, NVG0645.
Research Features published an article on us entitled "Nevrargenics: Neuroprotection, neuroplasticity, and neurorepair" about the background to, and summary of, our drug development programme.
Nevrargenics participates in Bio Europe
We were delighted to take part in Bio Europe Spring 2023 in Basel, Switzerland and have over 30 one-to-one meetings with pharmaceutical companies for potential deals.